Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)
Status unconfirmed · Phase 2 · Has a placebo group
Conditions studied: Autosomal Recessive Ichthyosis
In brief
KB105-02 is an intrasubject randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of KB105 in children and adults with autosomal recessive congenital ichthyosis (ARCI).
Key facts
- Study ID
- NCT05735158
- Run by
- Krystal Biotech, Inc.
- People needed
- 15
- Starts
- 2023-03-01
- Expected to finish
- 2024-04-01
- Last updated by the study team
- 2023-02-23
Who can join
Age: 1 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mission Dermatology — Rancho Santa Margarita, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.